Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 2,410,000 shares, a decline of 9.1% from the December 15th total of 2,650,000 shares. Based on an average trading volume of 324,600 shares, the days-to-cover ratio is presently 7.4 days. Currently, 22.1% of the company's stock are sold short.
A number of brokerages have issued reports on CRBP. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Corbus Pharmaceuticals in a research report on Monday, September 23rd. B. Riley cut their price target on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, September 20th. StockNews.com raised shares of Corbus Pharmaceuticals to a "sell" rating in a report on Monday, January 13th. Piper Sandler began coverage on shares of Corbus Pharmaceuticals in a research note on Monday, December 2nd. They issued an "overweight" rating and a $35.00 target price on the stock. Finally, Wedbush reiterated an "outperform" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Corbus Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $62.00.
Check Out Our Latest Stock Report on CRBP
A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in shares of Corbus Pharmaceuticals by 27.0% during the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock worth $114,000 after acquiring an additional 1,172 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Corbus Pharmaceuticals by 7.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,731 shares of the biopharmaceutical company's stock worth $469,000 after purchasing an additional 1,600 shares during the last quarter. FMR LLC increased its stake in shares of Corbus Pharmaceuticals by 33.0% in the third quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 2,486 shares during the period. Vestcor Inc bought a new stake in shares of Corbus Pharmaceuticals during the third quarter valued at approximately $64,000. Finally, Victory Capital Management Inc. boosted its position in shares of Corbus Pharmaceuticals by 29.9% during the third quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company's stock worth $511,000 after buying an additional 5,700 shares during the period. 64.64% of the stock is currently owned by institutional investors.
NASDAQ:CRBP opened at $11.92 on Friday. The stock has a 50 day moving average of $14.73 and a 200-day moving average of $31.94. The firm has a market capitalization of $145.19 million, a PE ratio of -2.54 and a beta of 2.63. Corbus Pharmaceuticals has a 52 week low of $6.20 and a 52 week high of $61.90.
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.